US Over-the-Counter (OTC) Drugs Market 2026 – 2035

The market size of the US over-the-counter (OTC) drugs market is estimated to be USD 39.77 billion in 2025 and forecasted to grow by USD 42.54 billion in 2026 up to about USD 75.93 billion by 2035 with the CAGR span of 6.60%. Though, this growth is fuelled by increased desire by consumers to self-medicate, increased prevalence of minor ailments and chronic conditions, the favorable FDA regulatory climate involving Rx-to-OTC switches, rising healthcare expenditure leading to the need for cheaper treatment options, the emerging e-commerce and online pharmacy opportunities, a heightened health awareness in consumers, and the emergence of new formulations.

Market Highlight

• US According to an estimation, the US will control about 34.8% of the global OTC drug market share in 2025, which is the largest single-country market in the world, with a total of about 97,289 FDA-approved OTC drugs as of November 2024.

• By the product type, the cough and cold products segment would take up approximately 28.4% of the market share in 2025 due to seasonal fluctuations and the prevalence of respiratory diseases.

• By product type, the vitamins and dietary supplements category is expanding with the most significant CAGR of 7.36% between 2026 and 2035, which is fueled by prevention trends with regards to health and wellness.

• By distribution channel, pharmacies that operate online are projected to grow at a CAGR of 9.12% within the forecasted timeframe between 2026 and 2035, with the highest market share of 58.9% in 2025; retail pharmacies were the highest contributors to the market share of 58.9%.

• By route of administration, oral formulations controlled 64.3% of market share in 2025 as topical applications are increasing by 7.82% CAGR as a result of localized curative inclinations.

• National Institute of Health data is that 93% of adults in the US treat minor illnesses with OTC drugs first before seeking professional assistance, and 85% of parents treat minor illnesses in children with OTC drugs.

Significant Growth Factors

The US Over-the-Counter (OTC) Drugs Market Trends present significant growth opportunities due to several factors:

• Escalating Prescription Drug Costs Driving Self-Medication Trends:

The explosive growth in prescription drug costs is the underlying cause of OTC market growth, as consumers are turning to more affordable, convenient sources of treatment through the use of alternatives to prescription drugs that provide cost savings yet still have clinical effectiveness. The American Journal of Health-System Pharmacy states that spending on pharmaceuticals in the United States grew by 13.6% in 2022-2023 to USD 722.5 billion in total spending and that the price of 4,264 medications rose in 2022-2023, putting an enormous economic burden on the population that forces consumers to choose less expensive OTCs to treat treatable conditions that do not need physician management. In 2021, the US prescriptive drug expenditure was estimated at USD 603 billion, with the outlook showing 2 percent growth in 2023 and 10-12-percent rise in 2024, representing a growing cost burden that is making OTC drugs an even more attractive option to consumers who want to evade high costs on prescriptive medications, doctor visitation, and insurance co-payment.

The survey data from GoodRx Research released in June 2025 indicated that a higher proportion of the American population is now worried about the cost of their drugs in 2025 (38%) than in 2024 (27%), and that 42% of citizens in 2025 reported changing the way they handled their prescriptions due to cost (compared to 34% in 2024), indicating financial pressures that will increase demand for low-cost OTC options. The survey found 67% of Americans who fill prescriptions claimed out-of-pocket fees amounted to at least a small financial burden, and 25% of them were taking credit card debt to cover health care costs in 2025 compared to 22% a year later, illustrating the financial strain that influenced consumers to replace OTC drugs with prescription drugs whenever it was appropriate in clinics, controlling minor illnesses without resorting to medical care.

Research studies affirm the prevalence of self-medication is rapidly increasing with rates ranging between 11.2 and 93.7% across the world, with the Journal of Environmental and Public Health reporting a prevalence of over 50% in India with the most developed OTC market infrastructure, and BMJ Open Journal reporting 85.4% prevalence in Ibadan, Nigeria in May 2023 with 11.2 to 93.7% prevalence being the lowest and highest prevalence rates of self-medication respectively. The research conducted by the National Institute of Health indicates that 93% of adults in the United States would use over-the-counter medications to treat minor illnesses rather than seeking professional medical care and 85% of parents would treat minor illnesses in their children using over-the-counter drugs, proving cultural acceptance and preference of the self-treatment approach that avoids making unnecessary visits to healthcare professionals and leaves the treatment of simple health issues to consumers themselves who can use readily available pharmaceutical products to manage simple health conditions.

• Favorable FDA Regulatory Framework and Accelerating Rx-to-OTC Switches:

Government regulatory frameworks supporting OTC drug development by creating easier approval processes, broadening Rx-to-OTC switching programs, introducing new regulatory structures such as Additional Condition of Non-prescription Use (ACNU), and consumer safety in regulation constitute key growth forces generating larger product access, more treatment choices, and better consumer access to effective drugs that previously needed prescription.

In January 2025, the US Food and Drug Administration authorized a new groundbreaking rule to make more prescription drugs over-the-counter through a process known as Additional Condition of Non-prescription Use (ACNU), allowing digital tools to direct self-selection as complex molecules that have been converted to software programs become regulatory compliance mechanisms, which is a paradigm shift that would enable OTC access to sophisticated treatment that was formerly only available by prescription-only status. The ACNU pathway introduced by the FDA in December 2024 enables some prescription drugs such as analgesics to transition to OTC status without the full requirements of a New Drug Application, supporting the self-care model, relieving the pressure on the emergency department, and expediting the availability of novel OTC products that meet unmet consumer needs with an innovative active ingredient or delivery method that was not previously found in non-prescription formulations. By November 18, 2024, the FDA has approved around 97,289 OTC drugs, which reflect an enormous infrastructure in the market to support consumer healthcare needs with fully regulated, quality-assured pharmaceutical products of various kinds including analgesics, cold and decongestant drugs, digestive health, skin conditions, nutritionals, and more.

The trend of regulatory encouragement of prescription to OTC switches is ever accelerating and the FDA is rapidly approving prescription-to-OTC switches in which post-market safety data has been presented to show acceptable risk-benefit profiles to allow consumer use without professional oversight, with the improvement of consumer health literacy, a requirement of clear labeling, and availability of pharmacist consultation to ensure proper use and increased access to effective therapies reducing healthcare costs and improving the health outcomes of populations through preventive self-care. The positive regulatory climate also covers the area of product innovation where the FDA is encouraging the development of new OTC formulations such as new combinations, alternative dosage situations, new delivery systems and new products targeting specific consumer needs to spur market growth with constant renewal of the product pipeline to keep consumers interested in the category and to encourage category development and therapeutic innovation to convert prescription drug innovations into new over the counter analogs.

• Growing Consumer Health Consciousness and Preventive Care Adoption:

Increments in consumer awareness of personal health management, higher adoption of preventive healthcare strategies, health literacy via digital access to information, and cultural change toward wellness and self-care are strong drivers on the demand side, with consumers managing their health conditions, preventing the development of diseases, and maximizing wellness by using OTC products such as vitamins, supplements, and prophylactic treatment of health issues before they start causing challenges that demand medical care. The segment with the highest growth rate of 7.36% CAGR between 2026 and 2035 is the vitamins and dietary supplements category, which is indicative of post-pandemic immunity awareness and a general shift towards prevention over treatment of diseases, with consumers spending on immune-enhancing products with elderberry, vitamin C, zinc, probiotics and herbal components as a means of boosting natural immunity against infectious diseases and ensuring optimal health instead of simply treating the disease when they have it.

Consumer behavior to expend on OTC drugs is rising steadily due to the growing appreciation of the importance of treating the body as an investment, not as an expense, discretionary income to spend on wellness products, the demand for convenient self-care solutions as an anti-busy lifestyle, and the belief in the safety and effectiveness of OTC products that is supported by the FDA, evidence-based formulations, and clear labeling that allow people to make informed decisions without consulting the doctor. E-health, the hybrid of virtual consultation and OTC medication sales, is becoming increasingly popular, with 19% of consumers using online shopping for medications according to YouGov data, fast delivery services are especially popular among women (31%), and the benefits of convenience, privacy, price visibility, and home delivery that e-commerce systems offer are more than traditional brick and mortar visits to pharmacies (need transportation to the physical location, wait times, and embarrassment at buying sensitive health commodities).

The explosion in demand of OTC immune support products during the viral seasons, the accelerated growth of plant based and organic supplements due to the wellness-based millennials, the increasing utilization of personalized dosage packaging and subscriptions among chronic OTC medication users, and the growth of own label OTC offerings competing based on price and target formulations all reflect market sophistication and consumer segmentation that create unique growth opportunities across high-end, average income, and low-end product lines.

What are the Major Advances Changing the US OTC Drugs Market Today?

• Artificial Intelligence Integration and Digital Health Convergence:

The integration of artificial intelligence into OTC drug discovery, patient education, pharmacist decision support, supply chain optimization, and personalized recommendations is the future innovation that is transforming consumer selection, purchase, and use of non-prescription drugs, increasing safety, improving adherence, and generating data-driven insights to inform product development and marketing strategies. The market analysis shows that artificial intelligence can transform the healthcare sector and radically change the healthcare landscape, making OTC drugs more effective, more accessible, and more accurate with the help of intelligent recommendation systems that read the symptoms and medical history of a consumer and prescribe the right products without causing any adverse events and the presence of contraindications and possible drug interactions.

The analytics based on AI allow pharmaceutical companies to track price behavior, positioning, and promotions of their competitors in real-time, allowing them to stay competitive with dynamic pricing optimization, inventory management to guarantee product availability and reduce wastage, and demand forecasts to support production planning to ensure they have just enough capacity to meet the demand during periods of peaks and have surplus capacity during times of low demand. Implementation of OTC product recommendations into AI-based telemedicine platforms that provide individuals who visit the virtual healthcare environment with evidence-based advice on self-treatment, professional assessment of OTC product use and referrals to a physician when symptoms suggest that the case may be addressed by prescription care, the continuum of care facilitates appropriate OTC use coupled with patient safety. Machine learning algorithms process large volumes of consumer buying patterns, symptom presentation, treatment results, and adverse event reporting to enhance their insights into new product development, formulation enhancement, label changes, and marketing messages that will appeal to specific demographics and meet regulatory needs and consumer anxieties regarding safety, efficacy, and correct usage. NLP technologies make it possible to use AI chatbots that can provide 24/7 consumer support with answering product questions, dosing advice, contraindication checks, and symptom evaluation, placing the pharmacist and customer service representative under less strain and consumers more at ease when they need to make an informed self-care choice, especially after hours when professional conversation is not possible.

• E-Commerce Expansion and Omnichannel Distribution Strategies:

The fast rise of online pharmacies, direct-to-consumer sales platforms, subscription-based services, as well as same-day delivery services, is a dramatic change in the market, and the digital commerce is growing compared to its 23.67% of all OTC pharmaceutical revenue in 2025 as a projection of the high penetration rates of the channel, based on consumer interests in convenience, price transparency, discrete purchases, and wide-ranging product assortment unavailable in the physical retail space.

The online pharmacies which are in the fastest-growing segment at 9.12% CAGR between 2026 and 2035 are indicative of increasing internet penetration, ubiquity of smartphones, enhancement of last-mile logistic operations, and consumer acceptance of purchasing health products online because platforms have price-comparison tools, consumer reviews, informational content, automated refills, and personal-setting recommendations, which make buying health products online better retail experiences than conventional pharmacies with limited inventory, higher prices, and limited operating hours. Expanding services to same-day delivery services in metropolitan areas allow consumers to get OTC medicines within hours of ordering and meet the needs of acute symptom management, remove transportation obstacles to mobility-limited groups, and compete with the immediacy of availability of traditional pharmacies, with Amazon Pharmacy, CVS, Walgreens, and niche platforms spending heavily on fulfillment infrastructure to support the promises of rapid delivery.

Ongoing subscriptions of chronic OTC drug users, such as vitamins, supplements, allergy drugs, pain relievers and digestive aids are very helpful since the continuous usage ensures continuity in treatment, the recurrent purchases are provided with discounts, the adherence is enhanced by the absence of reordering friction, and the recurrent sources of revenue are predictable to the retailers and manufacturers that created customer lifetime value instead of a single purchase. Omnichannel approaches that combine physical retailing, e-commerce, mobile apps, and telemedicine consultations provide the seamless consumer experiences that allow purchase path flexibility, where consumers research goods online, speak with pharmacists by video or in-store, buy via the channels of their choice, and receive support at various touchpoints that meet different needs and wishes depending on the customer situation. The awareness of the brand, the development of consumer confidence, the proper use of the product, and the traffic to online and in-store channels of retailing activities by pharmaceutical manufacturers USD 234 million, Instagram health influencers with 8.7% engagement rates based on digital marketing metrics, prove the effectiveness of social media in influencing consumer behavior and product acceptance.

• Product Innovation and Novel Formulation Development:

Continuous development of novel OTC drug delivery systems such as fast-dissolving tablets, transdermal patches, sublingual strips, slow-release capsules, chewable gummies and combination products is an important competitive differentiation where pharmaceutical companies are creating new systems of delivery that increase bioavailability, convenience, palatable taste, pediatric use or specificity to consumer preference leading to brand loyalty and market share. Oral products that make up 68.42% of volume in 2025 are complemented by fast moving topical formats with a CAGR of 8.72% through 2031 with topical gels, patches, and sprays being attractive to users that seek localized relief, do not undergo hepatic metabolism, have minimal systemic absorption, and like application convenience over oral dosing which requires access to water, the ability to swallow, and the digestive system processing that may be influenced by food products or gastrointestinal disorders.

Taste and convenience have grown more popular than efficacy as consumers consider options, with manufacturers repackaging traditional products as gummies, chewables, and patches, and companies developing new products that seem more like daily wellness rituals than a pharmaceutical intervention to ensure compliance in consumers who resist taking medication, especially with products where a daily dose is the key factor in long-term health benefits and require a long-term commitment of engagement with a daily dose that is decidedly unpleasant to consume. Oral disintegrating forms solve swallowing challenges in pediatrics and geriatrics and broaden the markets that can be addressed, fast-dissolving tablets allow the administration of drugs without water, and sublingual absorption that bypasses first-pass metabolism enhances the bioavailability of active ingredients and convenience facilitating use in other settings such as traveling, working, or where oral administration is not always possible help use disintegrating forms. Multi-symptom combination products: Multi-symptom products and combinations are products in a single formulation that relieve multiple symptoms, as decongestants, antihistamines, cough suppressants and pain relievers are combined to provide a simplified treatment regimen, an outcome that is generally desired by the consumer, as there is no need to use multiple products to achieve specific outcomes because it is available in one form. Multi-symptom products and combinations are also cited to confer additional benefits in the ease of use since multi-symptom products can be made to relieve various symptoms.

• Natural and Plant-Based Product Expansion:

The increasing consumer interest in natural, organic, and plant-based OTC alternatives to synthetics is an important market change, and supplements based on botanical sources, homeopathic products, probiotics, herbal preparations, and clean label products with no artificial additives or preservatives are growing faster in the market as a sign of the safer and more natural treatment options sought by the growing number of consumers interested in the product. Increasing consumer awareness concerning the ingredients of pharmaceutical products and a desire to find natural alternatives with it leads to the creation of an extensive variety of natural and herbal OTC products on the market, elderberry, vitamin C, zinc, echinacea, turmeric, ginger, and other botanical substances are used in immune support preparations and pain relievers marketed with a focus on natural sources, the use of the history of traditional medicine, and the holistic approach to health.

Plant-based and organic over-the-counter supplements led by wellness-oriented millennial consumers focus on sustainability, environmental responsibility, ethical sourcing, and transparency over product origin and manufacturing. They are willing to pay high prices for products with the above-stated attributes, which gives differentiation opportunities to brands that can communicate authenticity and commitment to natural formulations and sustainability in business activities, where values correspond to values-oriented consumers. Competing by price and targeted formulations, private label OTC pain relievers cold medicines, vitamins and other products in the retail pharmacy own-brand business segment build retail pharmacy own-brand portfolios with major chains such as CVS, Walgreens, and Walmart developing comprehensive own label OTC lines with 20-40% off the national brand price, without concession on quality through relationships with established manufacturers, and capturing price sensitivities in their consumer base and enhancing retail margins through higher own label profitability.

Category Wise Insights

By Product Type

Why Cough & Cold Products Lead the Market?

Cough and cold products are the most extensive segment in 2025 with an approximate share of 28.4% of the total market share. This supremacy is a manifestation of seasonal fluctuation that drives the steady increase in demand levels in the fall and winter season, a high rate of respiratory illnesses in most people, broad recognition of familiar brand names, and the necessity of symptom relief that promotes work productivity, school attendance, and quality of life during instances of viral illness. Cough and cold products conquer the largest market share due to seasonal variation with the prevalence of respiratory infections in colder seasons providing predictable demand curves; increased cases of respiratory infections that include influenza, rhinovirus, coronavirus variants and other pathogens that affect millions of Americans each year, and increased pediatric and geriatric populations that are more vulnerable to respiratory illnesses and need to manage symptoms safely and effectively by use of over the counter formulations targeted to vulnerable populations.

Combination products of decongestants to clear nasal congestion, antihistamines to clear runny noses and sneezing as well as cough suppressants to clear dry cough, expectorants to clear productive cough, and analgesics to eliminate fever and body aches are a combination of multiple products that offer a single combination to simplify treatment regimens and improve consumer convenience and compliance over individual products that may have complex dose regimens making them harder to use and reducing their effectiveness. Brand loyalty in the cough and cold segment is high as long as we have well-established products such as NyQuil, DayQuil, Theraflu, Mucinex, and Robitussin with high consumer recognition and decades of market experience and substantial investment in marketing creating top-of-mind awareness leading to repeat buying whenever there is an episode of illness and that the consumer wants to turn to familiar and reliable products and does not want to experiment with a new brand in the weak health condition.

Vitamins & dietary supplements with the highest growth with a 7.36% CAGR between the years 2026 and 2035 indicate the post-pandemic immunity awareness and shift in overall cultural response to illness, where consumers are spending on daily supplements to support immune health, bone density, heart health, cognitive abilities and the general well-being of the body and seeing the products as health insurance reflecting prevention of disease rather than treatment of the disease once they have developed.

By Distribution Channel

Why Retail Pharmacies Dominate the Market?

The largest segment is retail pharmacies, which will take up about 58.9% of market share in 2025. Such a pre-eminence is indicative of consumer preference to in-store shopping that allows them to access the product immediately, the availability of pharmacists to answer questions about product selection and how such products should be used, the development of shopping patterns where they rely on local pharmacy chains that they are used to, and the convenience of the retail pharmacies that are highly dispersed throughout the urban, suburban, and rural population.

As revealed in an article by YouGov data, released in 2024, two-thirds of consumers continue to want to visit physical pharmacies as they have medicinal requirements (66%), which illustrates an enduring attitude to physical retail despite the rise of e-commerce, fueled by the need to receive instant satisfaction of acute symptoms requiring immediate relief, want to be guided by a pharmacist and discuss their issues and needs with them, and make informed decisions, which would be impossible in the case of online-only shopping. Pharmacies Retail pharmacies offer reliable healthcare provision at a professional level, quality control, correct storage facilities that preserve the integrity of their products, and service provision to customers which offers product returns, exchanges, and solving of issues that creates more confidence in the safety and effectiveness of the purchases made by a customer than other less regulated means such as convenience stores or illegal online sellers which may dispense counterfeit or expired products to their customers. Large pharmacy chains such as CVS Health, Walgreens Boots Alliance, Rite Aid, and independent pharmacies have about 40,000 outlets across the nation that provide extensive geographical coverage that provides most Americans with short-distance distances of retail pharmacy, acute illness emergencies, and integration with prescription filling services that consolidate pharmaceutical purchases in a single trusted provider.

With internet penetration, mobile commerce through smartphone omnipresence, better logistics, such as same-day delivery in metropolitan regions, price transparency via comparison shopping applications, the sensitivity of health purchases, and convenience, eliminating the need to travel to a store to shop time, pharmacy operating hours, and wait time, online pharmacies have the fastest growth at 9.12% CAGR between 2026 and 2035.

By Route of Administration

Why Oral Formulations Dominate the Market?

The biggest segment is the oral route, which will take up about 64.3% of the market share in 2025. This domination is based on the familiarity and comfort of consumers with tablets, capsules, and liquid preparations, administration without special equipment or methods, applicability in the large spectrum of treatment classes, and an existing system of manufacturing oral dosage preparations that allows competitive pricing and extensive product distribution. Oral route leads the market due to its safety profile which has been well established with decades of clinical use, convenience which does not need special administration skills or devices which allows self-medication with various populations such as children and the elderly; and its full regulation by a regulatory structure to guarantee quality, efficacy and proper labeling that promote consumer confidence and informed use.

Tablets and capsules offer accurate dosage, stability to allow long shelf life, portability to facilitate easy transportation and discretionary usage, and manufacturing economies of scale to allow low production to support low prices and value propositions in general to support high frequency of purchase by mass-market OTC products. Particularly in pediatric populations who use this type of dosing form because they are unable to swallow a solid dosage, the elderly who have dysphagia or swallowing disabilities, and patients who want to control their dosing or have been taught that a liquid dose is an effective route of administration, with flavorings to mask bad flavours making palatability and adherence especially crucial in children who have medications that can be treated by appropriate dosing but suffer taste aversion.

Topical applications with the highest growth rate at 7.82% CAGR are due to localized delivery of treatment for pain, skin disease, and inflammation where superior penetration and therapeutic results are achieved with target delivery and convenience of topical application through the use of no water and without the need to swallow, advances in transdermal patches, medicated gels, and improved delivery systems.

Report Scope

Economic Impact Analysis

How Significant is the Industry's Economic Contribution?

The US OTC drug market is a significant part of the healthcare sector with a valuation of USD 39.77 billion in 2025 and a further USD 75.93 billion in 2035 and strong growth, indicating healthcare autonomy to consumers, physician overload due to minor illnesses, cost savings to the healthcare system, and employment in over 60 functions of the entire industry ecosystem. A National Center for Biotechnology Information publication shows that OTC drugs in the United States save about USD 100 billion a year compared to prescription drugs and the cost of seeking doctor attention, thus proving to be of enormous economic significance, as the population avoids healthcare use, unnecessary emergency room visits in case of minor illnesses that could be cured using non-prescription drugs, and doctor appointments in case of minor illnesses that could be treated with non-prescription drugs.

The economic aspect covers not only the direct market revenue but also the healthcare cost containment by accessible and affordable treatments to prevent a condition escalation, requiring costly medical care, and the productivity factors by allowing workers and students to proceed with normal tasks during minor illnesses instead of absence from work or school and insurance claims through the purchase of OTCs out of pocket lowers the risk to the premiums and the medical burden of health systems. Creation of jobs in the ecosystem of the OTC industry encompasses pharmaceutical manufacturing work at plants that make active pharmaceutical compounds and finished dosage forms, quality control and regulatory compliance work to ensure safety and effectiveness of the products, research and development work to design new products and refine existing formulations, sales and marketing to promote the products to the retailers and consumers, and pharmacy work in retail to sell the products and give consumer advice. OTC drug consumer buying reflects discretionary spending on healthcare services signifying health consciousness, preference toward preventive care over treatment, and readiness to invest in wellness instead of treatment as long as population health consciousness and their cultural shift to personal health responsibility complement the role of professional medical care, depending on the severity of the conditions and the complexity of clinical procedures.

What is the Industry's Innovation and Regulatory Impact?

OTC drug development is the driver behind therapeutic innovation, prescription-to-OTC switch introductions of sophisticated molecules to the consumer market to enable self-treatment of previously physician-managed conditions, the development of new chemical entities specifically to exploit OTC markets, and reformulations to make molecules easier to take, tastier, faster acting, or longer acting to allow competitive differentiation and introduction of new categories. The systems of FDA regulations of OTC drugs provide the safety of consumers and the market accessibility through the application of the monograph system by which the standards of common ingredients and therapeutic categories are established, the new drug application process where the active ingredient or indication is novel, and the ACNU pathway where the technology is used to select the consumers in a more complex way with the maintenance of the appropriate use through the digital guidance tools that represent the regulatory innovations that are paralleled with the technological capabilities.

Quality in all parts of the OTC supply chain such as good manufacturing practices, post-market surveillance of adverse events and product quality problems, labeling with clear instructions to use products and safety warnings, and enforcement with off label and unsafe products out of the market protect the health of the population and consumer confidence in the safety of OTC medicines to promote further market growth and further development of the category. The international trade of OTC products covers exporting to international markets where the US brands are well known to be of good quality and innovation, importing of ingredients and finished products by manufacturing plants located in various markets around the world that form complex supply chains with cost saving measures, and the multinational pharmaceutical companies that operate in many markets which exploit the large market to enforce efficiencies that are beneficial to the consumer in the US through competitive pricing and continuous product innovation due to the competition in the global markets.

Top Players in the Market

• Johnson & Johnson Services Inc.

• Bayer AG

• GlaxoSmithKline PLC (Haleon)

• Sanofi S.A.

• Pfizer Inc.

• Reckitt Benckiser Group plc

• Kenvue Brands LLC

• Novartis AG

• Boehringer Ingelheim

• Takeda Pharmaceutical Company

• Others

Key Developments

The market has undergone significant developments as industry participants seek to expand capabilities and enhance product offerings.

• In April 2025: Kingsway Pharmaceuticals will release PBZ OTC Pyribenzamine Antihistamine Cream, the first new topical antihistamine in target stores in the United States, with Tripelennamine HCL, to treat pain and discomfort caused by insect bites, poison ivy, and sunburns, adding to the topical OTC treatment offerings.

• In March 2025: Glenmark Pharmaceuticals declared the introduction of Polyethylene Glycol 3350 Powder for Solution into the US market as an OTC product, which will provide osmotic laxative to prevent and treat occasional constipation as a generic version of MiraLAX with annual sales of USD 555.7 million, indicating the opportunities of using generic OTC products.

• In January 2025: US Food and Drug Administration issued a revolutionary new regulation allowing more prescription drugs to be sold over-the-counter via the Additional Condition of Non-prescription Use (ACNU) process, which marks revolutionary progress in regulation to allow consumers to have access to highly complicated treatment via technology-controlled selection.

These strategic operations have enabled firms to consolidate market shares, diversify product lines, increase consumer accessibility, and exploit growth prospects in the fast growing market.

The US Over-the-Counter (OTC) Drugs Market is segmented as follows:

By Product Type

• Cough & Cold Products

o   Decongestants

o   Antihistamines

o   Cough Suppressants

o   Expectorants

• Analgesics

• Vitamins & Dietary Supplements

• Dermatology Products

• Gastrointestinal Products

• Other Products

By Form

• Tablets & Capsules

• Liquids & Syrups

• Ointments & Creams

• Sprays

• Other Forms (Gummies, Patches, Strips)

By Distribution Channel

• Retail Pharmacies

• Online Pharmacies

• Hospital Pharmacies

• Other Channels (Supermarkets, Convenience Stores)

By Route of Administration

• Oral

• Topical

• Parenteral

• Other Routes (Nasal, Inhalation)